Cascade screening 27 items
Testing relatives of index patients with high Lp(a): the Swedish programmes (LipoaScreen, STRIREG) and the guideline recommendations.
Studies
- The 2022 EAS consensus statement on Lp(a) in ASCVD and aortic stenosis (Kronenberg, Mora, Stroes et al., EHJ 2022)
- First-degree relatives of people with elevated Lp(a) have more MACE: Swedish registry cohort (Kindborg et al., EHJ 2026)
- NLA focused update 2024: measure Lp(a) at least once in every adult, with three risk bands (Koschinsky et al., J Clin Lipidol 2024)
- Lp(a) predicts cardiovascular disease in familial hypercholesterolaemia independent of the LDLR mutation: SAFEHEART (Alonso et al., JACC 2014)
- Cascade screening for Lp(a) from coronary patients: three relatives to screen per case found (Littmann et al., Atherosclerosis 2026)
- HEART UK consensus statement on Lp(a): a call to action (Cegla et al., Atherosclerosis 2019)
- Canadian Cardiovascular Society practical framework for Lp(a) screening, risk assessment and management (Can J Cardiol 2026)
- Cascade screening yields elevated Lp(a) in 47% of first-degree relatives, a 7.4-fold higher odds than unrelated individuals, in 52,418 UK Biobank participants (JAMA Cardiol 2023)
- Testing for Lp(a) during FH cascade screening finds new high-Lp(a) relatives and quadruples cardiovascular risk when both are present, SAFEHEART study of 2,927 relatives (J Am Coll Cardiol 2019)
- Cascade screening for elevated Lp(a) in relatives of children who visited the pediatric lipid clinic: yield of daily clinical practice
- Cascade testing for FH finds a new case of elevated Lp(a) for every 2.1-2.4 relatives tested, a review proposing a combined FH-Lp(a) care model (Front Genet 2022)
- Cascade testing for both FH and elevated Lp(a) uncovers a new case of either every 1.5-2.1 relatives tested, in 162 family members (Atherosclerosis 2022)
- Lp(a) drives premature cardiovascular disease even at goal LDL-C, review calls for universal testing and cascade screening (Eur J Prev Cardiol 2026)
- Lipoprotein(a) levels in children with hypercholesterolemia
- Routine Lp(a) testing changed management in most UK lipid clinic patients above 50 mg/dL, even without an Lp(a)-specific drug (Curr Med Res Opin 2026)
- Amsterdam UMC review finds cascade screening for elevated Lp(a) needs as few as 1.3 relatives tested per new case found (Curr Opin Lipidol 2024)
- HER(a) study finds 59.4% of first-degree relatives of high-Lp(a) ACS patients also have elevated Lp(a) (J Clin Med 2024)
- Only 81% of surveyed UK lipid clinics can measure Lp(a), and reporting units still vary widely, a national survey (J Clin Lipidol 2024)
- Testing every adult once for Lp(a), cascade screening relatives, and PCSK9 inhibition on top of statins in high-risk patients, a clinical review (Prog Cardiovasc Dis 2024)
- Cascade testing for Lp(a) yields 4x more elevated cases when starting from FH index patients who also have high Lp(a), in 103 children and adolescents (J Clin Lipidol 2024)
- Testing and treating Lp(a) is clinically actionable today via cascade screening and PCSK9 inhibition or apheresis, a review argues (Curr Cardiol Rep 2023)
- Lp(a) reaches adult levels by age 2 and stays stable for life, supporting a single universal screening test in youth aged 9-11 or 17-21, a review (Curr Atheroscler Rep 2023)
- Children with FH and Lp(a) above 30 mg/dL are nearly twice as likely to have family history of premature cardiovascular disease, LIPIGEN paediatric data on 653 children (Atherosclerosis 2022)
- Familial hypercholesterolaemia doubles cardiovascular risk when Lp(a) is also elevated, making cascade screening a key opportunity to catch both, a review (Curr Atheroscler Rep 2022)
- From Phenotype to Genotype and Beyond: Insights into Familial Hypercholesterolemia and Familial Hypertriglyceridemia
- Universal Lp(a) screening meets nearly every criterion except outcome-trial proof that lowering it helps, a review of detection strategies (Curr Opin Endocrinol Diabetes Obes 2023)
Video and podcasts